| Primary |
| Drug Use For Unknown Indication |
41.1% |
| Product Used For Unknown Indication |
16.6% |
| Sepsis |
11.6% |
| Infection |
5.0% |
| Lung Infection |
3.1% |
| Pain |
2.9% |
| Prophylaxis |
2.4% |
| Antibiotic Therapy |
2.1% |
| Pyrexia |
1.9% |
| Bone Marrow Transplant |
1.4% |
| Colostomy Infection |
1.4% |
| Abscess |
1.2% |
| Amputation |
1.2% |
| Anxiety |
1.2% |
| Diffuse Large B-cell Lymphoma |
1.2% |
| Hyperthermia |
1.2% |
| Lung Disorder |
1.2% |
| Pseudomonas Infection |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
| Antiretroviral Therapy |
1.0% |
|
| Toxic Skin Eruption |
13.8% |
| Thrombocytopenia |
11.0% |
| Vomiting |
9.2% |
| Pyrexia |
8.3% |
| Rash Maculo-papular |
5.5% |
| Convulsion |
4.6% |
| Pharmaceutical Product Complaint |
4.6% |
| Renal Failure |
4.6% |
| Stevens-johnson Syndrome |
4.6% |
| Urticaria |
4.6% |
| Renal Failure Acute |
3.7% |
| Respiratory Failure |
3.7% |
| Status Epilepticus |
3.7% |
| Wheezing |
3.7% |
| Respiratory Distress |
2.8% |
| Skin Exfoliation |
2.8% |
| Toxic Epidermal Necrolysis |
2.8% |
| Transaminases Increased |
2.8% |
| Dermatitis Exfoliative |
1.8% |
| Diarrhoea |
1.8% |
|
| Secondary |
| Product Used For Unknown Indication |
25.3% |
| Drug Use For Unknown Indication |
11.7% |
| Unevaluable Event |
9.5% |
| Pneumonia |
7.1% |
| Acute Myeloid Leukaemia |
7.0% |
| Pyrexia |
5.1% |
| Bronchopulmonary Aspergillosis |
4.9% |
| Dermo-hypodermitis |
4.6% |
| Sepsis |
4.4% |
| Pain |
3.2% |
| Lung Disorder |
2.6% |
| Prophylaxis |
2.3% |
| Lymphoma |
2.0% |
| Pseudomonas Infection |
1.9% |
| Antibiotic Therapy |
1.5% |
| Diabetic Foot |
1.5% |
| Acute Lymphocytic Leukaemia |
1.4% |
| Viral Infection |
1.4% |
| Infection |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
|
| Toxic Epidermal Necrolysis |
16.4% |
| Skin Exfoliation |
14.7% |
| Thrombocytopenia |
8.6% |
| Renal Failure Acute |
5.2% |
| Toxic Skin Eruption |
5.2% |
| Logorrhoea |
4.3% |
| Pancreatitis Acute |
4.3% |
| Rash |
4.3% |
| Renal Tubular Necrosis |
4.3% |
| Transaminases Increased |
4.3% |
| Clostridium Difficile Colitis |
3.4% |
| Urticaria Papular |
3.4% |
| Ventricular Fibrillation |
3.4% |
| Cholestasis |
2.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.6% |
| Pyrexia |
2.6% |
| Rash Maculo-papular |
2.6% |
| Renal Failure |
2.6% |
| Stevens-johnson Syndrome |
2.6% |
| Vomiting |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
37.1% |
| Product Used For Unknown Indication |
11.8% |
| Acute Myeloid Leukaemia |
4.7% |
| Pneumonia |
4.6% |
| Sepsis |
4.6% |
| Prophylaxis |
4.2% |
| Acute Lymphocytic Leukaemia |
3.6% |
| Hyperthermia |
3.2% |
| Osteitis |
3.2% |
| Unevaluable Event |
3.2% |
| Aspergillosis |
2.8% |
| Pyrexia |
2.7% |
| Anaemia |
2.1% |
| Skin Infection |
1.9% |
| Soft Tissue Infection |
1.9% |
| Cerebrovascular Accident Prophylaxis |
1.8% |
| Lung Disorder |
1.8% |
| Bronchitis |
1.6% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Non-small Cell Lung Cancer |
1.6% |
|
| Thrombocytopenia |
17.9% |
| Sepsis |
11.1% |
| Respiratory Failure |
8.5% |
| Pyrexia |
6.0% |
| Death |
4.3% |
| Pneumonia |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Arthralgia |
3.4% |
| Coma |
3.4% |
| Convulsion |
3.4% |
| Hepatic Enzyme Increased |
3.4% |
| Hepatotoxicity |
3.4% |
| Osteomyelitis |
3.4% |
| Pancytopenia |
3.4% |
| Pseudomonas Infection |
3.4% |
| Toxoplasmosis |
3.4% |
| Venoocclusive Disease |
3.4% |
| Venoocclusive Liver Disease |
3.4% |
| Vomiting |
3.4% |
| Bone Marrow Failure |
2.6% |
|
| Interacting |
| Diabetic Foot Infection |
75.0% |
| Atrial Fibrillation |
25.0% |
|
| International Normalised Ratio Increased |
100.0% |
|
